Drug developers reboot anti-NGF pain programmes.
Asher
A
Mullard
D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors*; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology
D000700:Analgesics; D061067:Antibodies, Monoclonal, Humanized; D020932:Nerve Growth Factor; C549319:tanezumab